Bank of New York Mellon Corp Decreases Stake in Edwards Lifesciences Corporation $EW

Bank of New York Mellon Corp cut its stake in Edwards Lifesciences Corporation (NYSE:EW) by 8.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,492,589 shares of the medical research company’s stock after selling 1,517,638 shares during the period. Bank of New York Mellon Corp’s holdings in Edwards Lifesciences were worth $1,491,243,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the 3rd quarter valued at approximately $25,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $28,000. Dorato Capital Management acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $29,000. N.E.W. Advisory Services LLC raised its stake in Edwards Lifesciences by 533.9% in the 4th quarter. N.E.W. Advisory Services LLC now owns 374 shares of the medical research company’s stock worth $32,000 after acquiring an additional 315 shares during the last quarter. Finally, Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.6%

Shares of EW opened at $87.59 on Wednesday. The company has a market capitalization of $50.44 billion, a price-to-earnings ratio of 46.59, a PEG ratio of 2.21 and a beta of 0.87. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $89.14. The stock’s 50-day moving average price is $81.85 and its 200-day moving average price is $83.02. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the company posted $0.64 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the sale, the vice president owned 33,934 shares in the company, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,371,239.08. The trade was a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 95,057 shares of company stock valued at $7,874,217 in the last three months. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on EW shares. UBS Group reiterated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Finally, Barclays reissued an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $95.96.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.